Mankind Pharma Ltd

Mankind Pharma Ltd has exhibited a notable shift in price momentum, moving from a mildly bearish to a mildly bullish technical trend, supported by a 4.83% gain on 22 Sep 2026. Despite mixed signals from key technical indicators such as MACD and RSI, the stock’s daily moving averages and Bollinger Bands suggest emerging strength, positioning it cautiously for investors amid a volatile pharmaceutical sector backdrop.

Mankind Pharma Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. The pharmaceutical mid-cap stock outperformed its sector peers with a robust 5.62% gain today, supported by a 34.43% jump in open interest, reflecting growing bullish sentiment and increased liquidity.

Mankind Pharma Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and potential directional bets. The stock outperformed its sector and broader indices, supported by rising volumes and sustained investor participation, reflecting renewed confidence in the mid-cap pharmaceutical player.

Mankind Pharma Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and potential directional bets. The stock outperformed its sector and broader indices, supported by rising volumes and sustained investor participation, reflecting renewed optimism in the mid-cap pharmaceutical player.

The Sensex advanced 0.77% on 21 Sep 2026, yet Mankind Pharma Ltd outpaced both the benchmark and its sector with a 5.17% intraday gain, reaching a high of Rs 2437. This 3.62 percentage-point outperformance highlights a stock-specific strength amid a broadly positive market environment.

Mankind Pharma Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and potential directional bets. The stock outperformed its sector and broader indices, supported by rising volumes and sustained investor participation, reflecting renewed confidence in the mid-cap pharmaceutical player.

Mankind Pharma Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a significant surge in open interest (OI) in its derivatives segment, signalling heightened market activity and potential directional bets. The stock outperformed its sector peers with a 4.83% gain today, supported by robust volume and rising investor participation, reflecting renewed optimism among traders and investors.

Mankind Pharma Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable surge in open interest (OI) in its derivatives segment, signalling increased market participation and potential directional bets. The stock has outperformed its sector peers with a 3.29% gain today, supported by rising volumes and sustained investor interest, reflecting a cautious yet optimistic market stance.

Mankind Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 03 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 September 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Mankind Pharma Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite a modest daily price increase of 0.85%, recent technical indicators suggest a nuanced outlook for investors, with mixed signals from MACD, RSI, moving averages, and other momentum tools.

Mankind Pharma Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend, reflecting a complex interplay of technical indicators. Despite a recent downgrade in its Mojo Grade from Buy to Hold, the pharmaceutical mid-cap continues to demonstrate resilience with a year-to-date return of 7.45%, outperforming the Sensex’s negative 9.71% over the same period.

Mankind Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 03 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 September 2026, providing investors with the latest insights into the company’s performance and outlook.

Mankind Pharma Ltd has experienced a subtle shift in its technical momentum, moving from a sideways trend to a mildly bullish stance, despite a complex mix of indicator signals. The mid-cap pharmaceutical company’s stock price has shown resilience with a 0.49% gain on 1 September 2026, closing at ₹2,399.00, reflecting nuanced market sentiment amid broader sector and index movements.

Mankind Pharma Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a more sideways trend as of late August 2026. This transition is underscored by a blend of bearish and neutral signals across key technical indicators such as MACD, RSI, Bollinger Bands, and moving averages, reflecting a complex market sentiment for the mid-cap pharmaceutical player.

Mankind Pharma Ltd has exhibited a subtle shift in price momentum, transitioning from a sideways trend to a mildly bullish stance, as reflected in recent technical indicators. Despite mixed signals from key oscillators such as MACD and RSI, the stock’s daily moving averages suggest an improving short-term outlook, prompting a downgrade in its Mojo Grade from Buy to Hold as of 3 August 2026.

Mankind Pharma Ltd has witnessed a notable 12.06% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. This surge accompanies a 1.58% gain in the stock price, outperforming its sector and the broader Sensex, suggesting renewed bullish sentiment in the mid-cap pharmaceutical player.

Mankind Pharma Ltd has witnessed a notable surge in open interest in its derivatives segment, signalling increased market activity and shifting investor positioning. The pharmaceutical mid-cap stock outperformed its sector peers and reversed a four-day decline, supported by rising delivery volumes and a narrow trading range, suggesting a potential directional shift in the near term.

Mankind Pharma Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable surge in open interest (OI) in its derivatives segment, signalling heightened market participation and shifting investor positioning. The stock outperformed its sector peers on 26 Aug 2026, reflecting renewed interest amid a backdrop of rising volumes and evolving technical trends.